BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma

Based on promising preclinical efficacy associated with the 20S proteasome inhibitor bortezomib in malignant pleural mesothelioma (MPM), two phase II clinical trials have been initiated (EORTC 08052 and ICORG 05–10). However, the potential mechanisms underlying resistance to this targeted drug in MP...

Descripción completa

Detalles Bibliográficos
Autores principales: Busacca, Sara, Chacko, Alex D., Klabatsa, Astero, Arthur, Kenneth, Sheaff, Michael, Gunasekharan, Vignesh K., Gorski, Julia J., El-Tanani, Mohamed, Broaddus, V. Courtney, Gaudino, Giovanni, Fennell, Dean A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676324/
https://www.ncbi.nlm.nih.gov/pubmed/23762382
http://dx.doi.org/10.1371/journal.pone.0065489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676324/
https://www.ncbi.nlm.nih.gov/pubmed/23762382
http://dx.doi.org/10.1371/journal.pone.0065489

Ejemplares similares